During the previous funding period we showed that glioma cells shrink as they invade the narrow extracellular spaces in the brain. Cell shrinkage is energetically driven by K+ and Cl- efflux through ion channels, which osmotically drives water out of the cell. We identified the underlying Cl-, and Ca2+-activated K+ channels and demonstrated that their pharmacological inhibition renders glioma cells unable to invade. One of the underlying channels, ClC-3, is regulated by chlorotoxin, a scorpion-derived peptide that inhibits Cl- currents and retards glioma invasion. These finding led us to initiate a Phase I/II clinical trial examining chlorotoxin as an anti-tumor drug in patients with malignant glioma which is now in Phase II. This competitive renewal application expands on unexpected observations made that mechanistically link Cl- movement to cell volume changes that occur in the context of cell proliferation and terminal cell proliferation, i.e. apoptosis. Specifically we hypothesize that glioma cells maintain elevated intracellular Cl- through active ion transport, which in turn allows cells to release Cl- through channels as they condense to enter mitosis. Cell shrinkage is directly caused by Cl- efflux and its inhibition inhibits proliferation. It also prevents condensation preceding apoptosis. Following each cell division cells re- establish their original volume through transport mediated Cl-/K+ and water uptake, which again is a necessary step for cell growth.
4 Specific aims are proposed that study the underlying Cl- channels and transporters, their mechanistic role in cell volume changes associated with proliferation and apoptosis as well as their regulation by phosphorylation and membrane trafficking. Finally, two FDA approved Cl- transport inhibitors will be examined preclinically using an animal model for malignant glioma.
This competitive renewal application expands on unexpected observations made that mechanistically link Cl- movement to cell volume changes that occur in the context of cell proliferation and terminal cell proliferation, i.e. apoptosis.
|Tewari, Bhanu P; Chaunsali, Lata; Campbell, Susan L et al. (2018) Perineuronal nets decrease membrane capacitance of peritumoral fast spiking interneurons in a model of epilepsy. Nat Commun 9:4724|
|Umans, Robyn A; Sontheimer, Harald (2018) Combating malignant astrocytes: Strategies mitigating tumor invasion. Neurosci Res 126:22-30|
|Simonds, G R; Marvin, E A; Apfel, L S et al. (2018) Clinical Neuroscience in Practice: An Experiential Learning Course for Undergraduates Offered by Neurosurgeons and Neuroscientists. J Undergrad Neurosci Educ 16:A112-A119|
|Haring, Alexander P; Sontheimer, Harald; Johnson, Blake N (2017) Microphysiological Human Brain and Neural Systems-on-a-Chip: Potential Alternatives to Small Animal Models and Emerging Platforms for Drug Discovery and Personalized Medicine. Stem Cell Rev 13:381-406|
|Robel, Stefanie; Sontheimer, Harald (2016) Glia as drivers of abnormal neuronal activity. Nat Neurosci 19:28-33|
|Thompson, Emily G; Sontheimer, Harald (2016) A role for ion channels in perivascular glioma invasion. Eur Biophys J 45:635-648|
|Campbell, Susan L; Robel, Stefanie; Cuddapah, Vishnu A et al. (2015) GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy. Glia 63:23-36|
|Kimbrough, Ian F; Robel, Stefanie; Roberson, Erik D et al. (2015) Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. Brain 138:3716-33|
|Robert, Stephanie M; Buckingham, Susan C; Campbell, Susan L et al. (2015) SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med 7:289ra86|
|Sontheimer, Harald (2015) Brain cancer: Tumour cells on neighbourhood watch. Nature 528:49-50|
Showing the most recent 10 out of 79 publications